Migraine Attack Treatment Response Molecular and Clinical BiOmarkers (MAMBO) Phase I

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-45
SponsorHospital Universitari Vall d'Hebron Research Institute

About this trial

The goal of this observational study is to identify differential traits in spontaneous migraine attacks that can help us predict the response to treatment with sumatriptan.

Participants will be asked to register the headache characteristics before and after taking sumatriptan and whether the treatment was effective or not during four migraine attacks.

Eligibility criteria

Qualifiers

Migraine with or without aura diagnosis according to ICHD-3 criteria

<8 migraine days per month

Be able to read, write and understand instructions.

Have internet access and mail address

Disqualifiers

Active preventive treatment for migraine

Active medication with an effect over the central nervous system

Serious physical or psychiatric condition

Cardiovascular or hepatic disease

Trial design

Treatments tested in this trial

  • Sumatriptan

Treatment groups

108 Participants
are divided into 1 treatment group

Locations

1
Hospital Universitari Vall d'Hebron Barcelona Spain

Sponsors and collaborators

Hospital Universitari Vall d'Hebron Research Institute

Lead sponsor

Instituto de Salud Carlos III

Collaborator